114 related articles for article (PubMed ID: 37645827)
1. Development of Gemcitabine-Modified miRNA Mimics as Cancer Therapeutics for Pancreatic Ductal Adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
bioRxiv; 2023 Aug; ():. PubMed ID: 37645827
[TBL] [Abstract][Full Text] [Related]
2. Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
Mol Ther Oncol; 2024 Mar; 32(1):200769. PubMed ID: 38596306
[TBL] [Abstract][Full Text] [Related]
3. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.
Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J
Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800
[TBL] [Abstract][Full Text] [Related]
4. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis.
Yun Z; Meng F; Li S; Zhang P
Aging (Albany NY); 2021 Feb; 13(4):6041-6054. PubMed ID: 33581689
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma.
Dang Z; Xu WH; Lu P; Wu N; Liu J; Ruan B; Zhou L; Song WJ; Dou KF
Int J Biol Sci; 2014; 10(7):733-45. PubMed ID: 25013381
[TBL] [Abstract][Full Text] [Related]
9. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
10. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Xu L; Ma X; Zhang X; Zhang C; Zhang Y; Gong S; Wu N; Zhang P; Feng X; Guo J; Zhao M; Ren Z; Zhang P
Mol Cancer; 2023 Dec; 22(1):195. PubMed ID: 38044421
[TBL] [Abstract][Full Text] [Related]
11. A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Zhang F; Yao Z; Jin P; Xu M; Hu Q; Chen Y; Que R; Liang T
Biomed Mater; 2023 Apr; 18(3):. PubMed ID: 36990101
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of the microRNAs and hub genes for pancreatic ductal adenocarcinoma by an integrated bioinformatic analysis.
Xin W; Fu Y; Chen L; Ding H; Feng T; Sun J; Qi Y; Hu Y; Fang Q; Fang L
J Gastrointest Oncol; 2023 Apr; 14(2):719-732. PubMed ID: 37201049
[TBL] [Abstract][Full Text] [Related]
13. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
14. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
15. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
Bandi N; Vassella E
Mol Cancer; 2011 May; 10():55. PubMed ID: 21575235
[TBL] [Abstract][Full Text] [Related]
16. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Sun Y; Wang P; Yang W; Shan Y; Zhang Q; Wu H
Cancer Biol Ther; 2019; 20(6):729-739. PubMed ID: 30915884
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of miR-15a and miR-214 in human pancreatic cancer.
Zhang XJ; Ye H; Zeng CW; He B; Zhang H; Chen YQ
J Hematol Oncol; 2010 Nov; 3():46. PubMed ID: 21106054
[TBL] [Abstract][Full Text] [Related]
18. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
19. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
